Pneumococcal Vaccination Impact on Pneumonia Mortality in Colombia

this 14-year time-series analysis, encompassing both pre-PCV10 and post-PCV10 data, provides valuable insights into the affect of pediatric pneumococcal vaccination on pneumonia mortality trends across various age groups in Colombia. The study revealed critically important reductions in age-specific pneumonia mortality rates among children under 5 years throughout the study period. Conversely, researchers observed no reduction in pneumonia mortality rates in unvaccinated age groups older than 5 years following the introduction of PCV10.

For infants aged < 1 year and children aged 1 to 4 years, the decreasing trend in age-specific mortality rate trends began prior to the PCV10 introduction. This suggests factors such as the earlier implementation of PCV7 for high-risk infants and improved nutrition in Colombia played a significant role [2, 3, 24, 25]. Developing immune systems make children especially vulnerable to nutritional deficiencies, which severely impact their overall health [3]. The Global burden of Disease (GBD) 2016 report identifies childhood wasting as the leading risk factor for mortality from lower respiratory infections in children under five, accounting for 61.4% of such deaths [3]. These findings align with previous studies in Latin America, demonstrating the effect of socioeconomic improvements and PCV introduction in preventing pneumonia-related mortality in young children[7[725,26, 27].

Unlike studies reporting reduction in pneumonia mortality in unvaccinated groups post-PCV introduction, this study did not observe this effect in individuals older than 5 years [12, 28]. These findings align with another study carried out in South American countries [17]. Interpreting the study findings in the context of serotyping data is crucial. In 2022, Colombia switched to PCV13 based on local surveillance data indicating that most pneumococcal disease cases were caused by serotypes not covered by PCV10, specifically serotypes 19 A, 3, and 6 C [18, 29]. This serotype replacement affected herd protection, as demonstrated by the increased prevalence of PCV13non PCV10 serotypes in unvaccinated older age groups in Colombia [8, 30]. Consequently, the observed effects in the study might not fully represent the broader potential for herd protection. It remains essential to continue evaluating circulating serotypes and ensuring vaccines are updated to cover the most prevalent and pathogenic strains.